Insulin Resistance
60 articles on Insulin Resistance, researched and written by the Shotlee Editorial Team from primary sources.
I Lost 5 Stone on Mounjaro — But Now I’ve Had Enough
Natalie Lavergne transformed her health and lost 5 stone using Mounjaro, but now plans to switch to the Wegovy pill. Discover the medical realities of stopping weight loss medication.
8 min read
MOTS-C: A Peptide for Obesity Beyond GLP-1s?
While GLP-1 agonists have dominated weight loss discussions, a new peptide called MOTS-C is emerging with its own unique potential for tackling obesity and improving metabolic health. This article delves into what MOTS-C is, how it works, and its current research status.
7 min read
Semaglutide Greenlit for MASH Liver Disease Treatment
The MHRA has granted conditional approval for semaglutide to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
7 min read
Wegovy for Children: Safety Concerns, Obesity Trends, and Expert Advice
An in-depth look at the controversial use of GLP-1 medications in pediatric patients, childhood obesity statistics, and long-term safety concerns highlighted by medical experts.
8 min read
Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?
A comprehensive review of clinical trials suggests that GLP-1 medications may offer reproductive benefits for men with obesity-related low testosterone, potentially surpassing traditional hormone replacement therapies.
7 min read
Cagrilintide + Semaglutide: A Promising Dual Approach for Type 2 Diabetes
New research presented at the American Diabetes Association meeting highlights the potential of combining cagrilintide, an amylin receptor agonist, with semaglutide for improved glycemic control in adults with type 2 diabetes.
7 min read
Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise
Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.
7 min read
Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym
For individuals struggling with difficult-to-control type 2 diabetes and weight management, even powerful GLP-1 medications might not be enough. New research highlights the significant role of hypercortisolism and the promising potential of Korlym in optimizing treatment outcomes.
6 min read
Semaglutide and Pregnancy: Understanding New Risks and Weight Rebound
A recent national database study reveals significant obstetric risks associated with semaglutide exposure before and during pregnancy, highlighting the importance of the weight rebound effect.
7 min read
Beyond the Injection: The Future of GLP-1 Therapies
GLP-1 receptor agonists have revolutionized weight loss and diabetes management, but researchers are continuously seeking ways to enhance their delivery. This article delves into cutting-edge advancements, from nanocarriers to microneedles, aiming to make these powerful therapies more effective, tolerable, and convenient.
7 min read
Beyond the 'Bridal Glow': The Real Story of Mounjaro & Weight Loss
As 'Mounjaro brides' become a trend, an endocrinologist unpacks the medical realities, risks, and ethical concerns surrounding using powerful weight-loss medications for cosmetic pre-wedding transformations.
9 min read
Beyond Willpower: Understanding Obesity's Metabolic Roots
Obesity is a complex, multi-organ disease, not a failure of willpower. This article delves into its metabolic underpinnings and outlines a practical approach to management, including modern medications and lifestyle adjustments.
7 min read
Cannabis for Weight Loss: Could It Be the Next Ozempic?
Researchers at UC Riverside have uncovered promising data linking cannabis oil to improved metabolic function and weight loss in mice, sparking debate about its potential as a future therapy alongside GLP-1 medications.
8 min read
Understanding Insulin Resistance: Beyond Blood Sugar
Insulin resistance is a critical metabolic condition affecting blood sugar regulation and potentially impacting brain function. This comprehensive guide delves into its causes, symptoms, and the vital role of lifestyle interventions.
8 min read
PCOS Renamed PMOS: A New Era for Endocrine Health
Polycystic Ovary Syndrome (PCOS), a condition affecting millions of women, is undergoing a significant renaming to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to better reflect the condition's complex interplay with endocrine and metabolic systems, potentially improving diagnosis and treatment.
8 min read
How One Woman Lost 55kg with PCOS Without Ozempic: The Role of Magnesium
Heather Marie lost 55kg managing PCOS and hypothyroidism through lifestyle and magnesium supplementation, avoiding injectables like Ozempic. Here is her story and the medical science behind it.
7 min read
Oral Semaglutide Shows Promise for Pediatric Type 2 Diabetes
Novo Nordisk recently unveiled compelling topline results from the PIONEER TEENS trial, suggesting that oral semaglutide could become the first oral GLP-1 Receptor Agonist (RA) therapy approved for children and adolescents managing Type 2 Diabetes (T2D). This development addresses a significant gap in pediatric endocrinology, offering a potentially more accessible treatment option.
6 min read
Preventing Weight Regain After GLP-1: The New Endoscopic Breakthrough
New research suggests an outpatient endoscopic procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Wegovy and Mounjaro.
3 min read
Aston Gynaecologist Investigates Ozempic, Mounjaro Impact on PCOS
A leading gynaecologist at Aston Medical School is probing whether GLP-1 drugs like Ozempic and Mounjaro could transform care for women with PCOS. With a £60,000 NHS grant, Dr Shagaf Bakour aims to evaluate their effects on metabolic health and fertility. This investigation highlights hope for better treatment pathways amid rising interest in these weight loss jabs.
5 min read
Duodenal Resurfacing May Prevent Weight Regain After Stopping Ozempic
New research presented at Digestive Disease Week 2026 suggests a minimally invasive 'gut reset' procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Ozempic and Wegovy. The findings address a major challenge in obesity treatment: weight regain after stopping therapy.
7 min read
Pfizer's Xianweiying GLP-1 Weight Loss Drug Pre-Order in China
Pfizer's GLP-1 weight management drug Xianweiying is available for pre-order on JD.com in China, intensifying rivalry in a market projected to reach billions. Priced at 489 yuan ($72) for a 1.2 ml injector pen with shipping from April 27, it challenges leaders like Novo Nordisk's Wegovy and Innovent's Xinermei. This move bolsters Pfizer's position via licensing from Sciwind.
5 min read
GLP-1s Don't Work for Everyone: What to Know If Not Seeing Results
Started GLP-1s for weight loss or blood sugar control but seeing no results? New research in Genome Medicine reveals that 10% of people carry PAM gene variants linked to weaker responses. Experts explain genetics, common pitfalls, testing, and effective alternatives to help you succeed.
7 min read
Luke Combs Rejects GLP-1 for Weight Loss: 'Not the Short Way'
Country music sensation Luke Combs is turning down GLP-1 medications for weight loss, opting for the hard road instead. In a candid New York Times interview, he shares fears about his appearance affecting his career and why 'that stuff scares me more than the benefits.' This stance highlights debates around quick fixes versus lifelong habits in weight management.
4 min read
Ozempic and GLP-1 Drugs: Heart Benefits and Personal Realities
Thirty million Americans—one in eight—are turning to GLP-1 drugs like Ozempic for weight management and more, with data showing a 20% reduced risk of heart attacks and strokes. But what happens when the weight doesn't budge, as in 10% of users? This personal story explores the hype, realities, and broader implications of these medications.
4 min read
Aston University Investigates Weight-Loss Drugs for PCOS Treatment
A gynaecologist at Aston University has won a £60,000 NHS research grant to probe the potential of weight-loss drugs like Ozempic and Mounjaro in treating polycystic ovary syndrome (PCOS). This initiative aims to evaluate their impact on metabolic health and fertility in affected women. Discover the project's details and why it matters for patient care.
6 min read
Shaughna Phillips' Weight Loss Journey: Body Positivity Amid Cellulite & Lipo...
Love Island star Shaughna Phillips is celebrating a 9kg weight loss over four months, sharing transparent before-and-after videos despite cellulite and lipoedema flare-ups. Rejecting Ozempic claims, she credits gym sessions, protein-focused eating, and her Shred It Plan. Her journey emphasizes progress over perfection for busy moms.
6 min read
Tirzepatide Lowers Blood Sugar and Weight Faster in Type 2 Diabetes Study
A groundbreaking study reveals tirzepatide outperforms semaglutide and insulin degludec in speeding up blood sugar control and weight loss for type 2 diabetes patients. Participants on tirzepatide hit HbA1c targets below 7% in just eight weeks, compared to twelve weeks for alternatives. These faster results could boost long-term adherence and health outcomes.
4 min read
Safely Buy GLP-1 Drugs Online: Key Facts Amid Ad Surge
Serena Williams' 2026 Super Bowl ad spotlighted her GLP-1 weight-loss journey, fueling massive online searches for drugs like Ozempic and Wegovy. With ads bombarding daily life and insurance often falling short, a booming online market offers cheaper options—but at what risk? Here's what you need to know to safely buy GLP-1 drugs online.
5 min read
Gut Reset Era 2026: Redefining Weight Loss and Digestive Health
In 2026, the gut reset era is transforming weight loss by linking it inseparably to digestive health and metabolism. No longer isolated goals, bloating, slow metabolism, and weight gain are addressed holistically for lasting results. From microbiome breakthroughs to personalized tech tools, this integrated approach promises better outcomes.
7 min read
'Gym Peptides Gave Me Diabetes': Actor's Story Reveals Dark Side
A disciplined 35-year-old film actor walked into a Mumbai clinic with Type 2 diabetes after two years of unregulated peptide injections for a muscular physique. Recommended by his gym trainer, drugs like MOTS-c and tamoxifen wreaked havoc, causing insulin resistance. Experts reveal the growing misuse in fitness circles and how to spot the risks.
6 min read
Why Mounjaro is Having a Moment: Content Creator's Weight Loss Story
Content creator Aishwarya Mohanraj's candid video about dropping from 74kg to 52kg in six months on Mounjaro has spotlighted the injectable drug. Amid PCOS and hypothyroidism challenges, her story shifts focus from Ozempic hype. But experts warn: pair it with lifestyle changes or risk weight regain.
5 min read
Ozempic Improves Liver Health Without Weight Loss, Study Finds
A groundbreaking study shows that Ozempic and Wegovy enhance liver health directly, bypassing the need for weight loss. Canadian researchers uncovered semaglutide's action on key liver cells, challenging old assumptions about GLP-1 therapies. This could transform care for metabolic liver diseases like MASH.
6 min read
Ozempic Isn't a Magic Fix: Semaglutide Risks in India
Semaglutide injections like Ozempic have arrived in India at low prices, exciting millions with diabetes and rising obesity. But experts like Dr. Gagandeep Singh caution it's no magic fix—weight returns upon stopping, muscle loss is common, and misuse risks malnutrition. Understand the real story behind these GLP-1 weight loss injections.
6 min read
Genetic Variants May Reduce GLP-1 Diabetes Drug Effectiveness
A new Stanford Medicine study uncovers why GLP-1 receptor agonists may not work as well for some Type 2 diabetes patients: certain genetic variants lead to GLP-1 resistance. Carried by about 10% of the population, these variants result in higher but less effective GLP-1 levels. This could guide faster, personalized treatment switches.
6 min read
Why Ozempic Doesn't Work for Everyone: Hidden Genetic Reason Found
Scientists have uncovered why Ozempic and similar GLP-1 drugs don't work for everyone: genetic variants in the PAM gene cause GLP-1 resistance in about 10% of people. Despite higher GLP-1 levels, these individuals show reduced drug effectiveness in lowering blood sugar. This breakthrough could pave the way for personalized treatment strategies.
5 min read
Hidden Reason Ozempic Fails for Some: GLP-1 Resistance Revealed
New research reveals a hidden genetic reason why Ozempic fails for some: GLP-1 resistance linked to PAM gene variants affecting 10% of the population. Despite higher GLP-1 levels, these individuals show reduced drug efficacy in lowering blood sugar. Discover the study's findings from humans, mice, and clinical trials.
7 min read
Americans Embrace Meat Industry's Protein Health Claims
More Americans are prioritizing meat for protein, with 75% seeing it as healthy—up from 64% in 2020. But experts like Tufts' Erin Hennessy caution against overfixating on meat amid industry pushes and RFK Jr.'s endorsements. Discover the health risks and smarter protein alternatives.
6 min read
Cheaper Generic Semaglutide in India: Experts Warn Against Quick-Fix Use
Cheaper generic semaglutide is transforming access to weight loss and diabetes treatment in India, priced at just Rs750 per weekly injection. However, experts caution against 'quick-fix' use without medical oversight, highlighting risks like 40% muscle loss from lean mass. Discover clinical evidence from STEP-1 and SELECT trials and why structured care is essential.
5 min read
MHRA Investigates UK Peptide Clinics Over Health Claims
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is probing peptide clinics for unlawful health claims on experimental therapies. A Guardian investigation uncovered websites touting benefits like tissue repair from BPC-157 despite scant human evidence. Clinics defend their practices amid rising interest in these injections.
5 min read
FDA Approves Foundayo Weight Loss Pill, Igniting GLP-1 Showdown
The FDA has approved Foundayo weight loss pill from Eli Lilly on April 1 (ET), introducing a flexible oral GLP-1 option for adults with obesity or weight-related conditions—no food or water restrictions needed. Trial data shows superior weight loss over Rybelsus, averaging 15-20 pounds vs. 8-11 pounds in diabetes patients. This approval sets up a new showdown in the GLP-1 market dominated by injections like Wegovy and Zepbound.
5 min read
MHRA Investigates UK Peptide Clinics Over Health Claims
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is investigating peptide clinics for making bold health claims about unregulated therapies. Clinics promote peptides like BPC-157 for injury recovery and MOTS-C for energy, despite scant human evidence. This Guardian-revealed probe highlights risks in the booming peptide market.
6 min read
Emcure Revises Poviztra Semaglutide Price to ₹3,999/Month in India
Emcure Pharmaceuticals is slashing the price of Poviztra semaglutide injection to ₹3,999 per month starting April 3, 2026, making this weight management therapy more accessible across India. As the first Indian firm offering this second brand of Novo Nordisk's semaglutide, Emcure aims to tackle the nation's obesity epidemic affecting over 600 million adults. Backed by 49 million patient years and 50 clinical trials, Poviztra promises validated support for obesity-linked conditions.
5 min read
India Issues Guidelines on GLP-1 Drugs Use, Risks, Regulations
The Government of India has issued comprehensive guidelines on GLP-1 drugs, addressing their use for type 2 diabetes and obesity, associated risks, and regulatory measures. With drugs like semaglutide and tirzepatide gaining popularity, authorities warn against unsupervised use due to serious side effects like pancreatitis. Strict surveillance ensures prescriptions only by specialists like endocrinologists.
6 min read
Gayle King Ozempic Rumors: 10-Year Weight Loss Photos Revisited
Gayle King has navigated a public weight loss rollercoaster over 10 years, mirroring Oprah's but without confirming GLP-1 meds like Ozempic. From Weight Watchers triumphs to soup fasts and Sports Illustrated swimsuit glory, her story highlights diet, exercise, and resilience. Speculation swirls around her recent gaunt look—Ozempic face or natural leanness?
5 min read
New Diabetes Drug UBT251 Beats Ozempic in Phase 2 Trial
In a Phase 2 clinical trial in China, Novo Nordisk's experimental drug UBT251 surpassed Ozempic, achieving greater reductions in blood sugar (up to 2.16% HbA1c drop) and body weight (up to 9.8% loss). This marks a potential advancement for type 2 diabetes management. Patients on semaglutide saw 1.77% HbA1c and 4.8% weight reductions, while placebo groups lagged behind.
5 min read
Jelly Roll Loses 275 Pounds: No Ozempic, Just Discipline
Country star Jelly Roll has dropped 275 pounds, going from 540 to 265 lbs without Ozempic or surgery—pure discipline, faith, and addressing root causes like emotional eating and high insulin. His Men's Health cover story details the real transformation. Now, skin removal surgery awaits as the next step.
5 min read
Ozempic Cuts Depression, Anxiety, and Addiction Risk: Study
A groundbreaking study reveals that Ozempic and other GLP-1 medications like semaglutide significantly lower risks of depression, anxiety, addiction, and even suicidal behavior. Analyzing nearly 100,000 people, researchers found up to 47% reductions in related hospital visits and work absences. This could transform treatment for those with overlapping metabolic and mental health issues.
5 min read
MGB's New Genetic Risk Calculator for Obesity: A Game Changer
Researchers at Mass General Brigham have launched a revolutionary genetic risk calculator that not only forecasts obesity and Type 2 diabetes but also their long-term health consequences. Powered by data from over 8.5 million participants worldwide, this polygenic risk score outperforms existing tools, especially in diverse populations. Discover why this could enable earlier interventions like GLP-1 medications.
5 min read
Quitting Ozempic? What Happens When You Stop: Weight Regain & Risks
Stopping Ozempic can lead to full weight regain in about 1.7 years, plus reversal of cardiovascular and metabolic benefits, warns a major BMJ review. Nearly 50% of users discontinue within a year due to side effects and high costs. Doctors urge consulting before quitting to protect your health gains.
5 min read
Side-by-Side Photos Show Vanessa Williams' 'Ozempic Face' Progression
Side-by-side photos of Vanessa Williams highlight her 'Ozempic face' transformation, marked by wrinkles and an 'Ozempic neck' after using Mounjaro for menopause-related weight gain. The first Black Miss America calls it a 'game-changer' at age 60. A plastic surgeon details how GLP-1 drugs affect facial fat and skin health.
5 min read
Why Layla Taylor Quit GLP-1s: Mormon Wives Star's Story
Layla Taylor, star of The Secret Lives of Mormon Wives, has stepped away from GLP-1 medications after using them as an unhealthy crutch for her lifelong eating disorder. Ahead of season 4, she opens up about hidden side effects like aching joints, falling hair, and constant fatigue that signaled her body was breaking down. Her story underscores the importance of monitoring GLP-1 use, especially with pre-existing conditions.
6 min read
GLP-1 RAs Linked to Lower Mortality in Brain Metastases, T2DM Patients
For patients battling cancer with brain metastases and type 2 diabetes, GLP-1 receptor agonists may offer a survival edge. A retrospective study of over 19,000 patients found GLP-1 RA users had significantly lower all-cause mortality (HR 0.63) after matching. This benefit held across major cancers and most GLP-1 RA types.
5 min read
Should You Take GLP-1 Drugs for Longevity?
A quote from The Economist's Style Guide warns against calling anything a panacea—yet GLP-1 drugs for type 2 diabetes and obesity are now eyed by healthy individuals for longevity. Is their time as a miracle cure finally here? This guide weighs the excitement against expert caution and real-world considerations.
4 min read
Mounjaro Shortage Harms Patients Amid Diet Craze: Supply Crisis
A surge in dieting demand has triggered shortages of Mounjaro's 5mg starting dose, making it hard for metabolic disease patients to access treatment. Clinics in Seoul report instability until late March, as non-reimbursed status leaves supply unmanaged. Patients like Mr. A face halted therapy despite proven benefits for diabetes control and weight loss.
6 min read
Fat Cells Burn Energy for Heat: Next Weight Loss Frontier
Fat tissue isn't just storage—it's a dynamic organ that can burn energy as heat, opening new doors for weight loss beyond appetite-suppressing drugs like Ozempic and Wegovy. Researchers are targeting brown and beige fat to boost calorie burn without triggering hunger. This could be the next era in metabolic therapies.
4 min read
This Week in Science: Ozempic's Joint Benefits, Superagers Secrets & More
This week's science news uncovers surprising benefits of Ozempic for joint health beyond weight loss, reveals why superagers stay sharp with more new brain neurons, and highlights food quality over diet type for heart protection. From cholesterol-lowering oatmeal diets to a universal nasal vaccine, these findings offer fresh hope for metabolic and cognitive health.
5 min read
Joan Collins, 92, Rejects Ozempic Over 'Disastrous Faces' and Needles
At 92, actress Joan Collins declares she'd 'never dream' of using Ozempic, citing 'too many disastrous faces' and her aversion to needles. This sparks discussion as Kelly Osbourne confronts cruel commentary on her look at the Brit Awards. Learn the medical context behind these celebrity views on GLP-1 drugs.
5 min read
Beyond Weight Loss: Ozempic Linked to Migraine Reduction, Study
GLP-1 receptor agonists like Ozempic, used for diabetes and weight loss, may offer relief for chronic migraine sufferers by cutting emergency department visits and medication needs. A new study compares them to topiramate, revealing promising associations in stabilizing migraine burden. Presented at the American Academy of Neurology's 2026 meeting, these findings highlight unexpected benefits beyond weight loss.
5 min read
PureHealth Research Launches Natural GLP-1 Support Collection
PureHealth Research has launched the Natural GLP-1 Support collection, providing a comprehensive, needle-free alternative to expensive synthetic GLP-1 injections. Led by the physician-approved GLP ON formula, it addresses three key GLP-1 pathways with clinically studied dosages. Discover how these natural supplements support weight management and metabolic function without prescriptions.
5 min read
Eli Lilly's Orforglipron: More Effective GLP-1 Pill for Weight Loss?
Eli Lilly's investigational GLP-1 pill, orforglipron, demonstrated greater weight loss and blood sugar control than oral semaglutide in a major phase 3 trial for type 2 diabetes. Patients lost 6-8% body weight compared to 4-5%, though with higher GI side effects. This could signal a shift toward more effective oral therapies.
6 min read